Display options
Cite
Ayala P, Uchida M, Akiyoshi K, et al. Androgen receptor overexpression is neuroprotective in experimental stroke. Transl Stroke Res. 2011;2(3):346-57doi: 10.1007/s12975-011-0079-z.
Ayala, P., Uchida, M., Akiyoshi, K., Cheng, J., Hashimoto, J., Jia, T., Ronnekleiv, O. K., Murphy, S. J., Wiren, K. M., & Hurn, P. D. (2011). Androgen receptor overexpression is neuroprotective in experimental stroke. Translational stroke research, 2(3), 346-57. https://doi.org/10.1007/s12975-011-0079-z
Ayala, Patricia, et al. "Androgen receptor overexpression is neuroprotective in experimental stroke." Translational stroke research vol. 2,3 (2011): 346-57. doi: https://doi.org/10.1007/s12975-011-0079-z
Ayala P, Uchida M, Akiyoshi K, Cheng J, Hashimoto J, Jia T, Ronnekleiv OK, Murphy SJ, Wiren KM, Hurn PD. Androgen receptor overexpression is neuroprotective in experimental stroke. Transl Stroke Res. 2011 Sep;2(3):346-57. doi: 10.1007/s12975-011-0079-z. Epub 2011 Apr 15. PMID: 24323653.
Copy Download .nbib Format: NLM
Share it on

Transl Stroke Res. 2011 Sep;2(3):346-57. doi: 10.1007/s12975-011-0079-z. Epub 2011 Apr 15.

Androgen receptor overexpression is neuroprotective in experimental stroke.

Translational stroke research

Patricia Ayala, Masayoshi Uchida, Kozaburo Akiyoshi, Jian Cheng, Joel Hashimoto, Taiping Jia, Oline K Ronnekleiv, Stephanie J Murphy, Kristine M Wiren, Patricia D Hurn

Affiliations

  1. Department of Anesthesiology and Perioperative Medicine, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR, 97239-3098, USA, [email protected].

PMID: 24323653 DOI: 10.1007/s12975-011-0079-z

Abstract

Male sex is a known risk factor in human stroke. However, the role of the cognate receptor for androgens-the androgen receptor (AR)-in stroke outcome remains unclear. Here, we found that AR mRNA is downregulated in the peri-infarct tissue of gonadally intact male mice subjected to middle cerebral artery occlusion (MCAO) and 6 h reperfusion. We then used genetically engineered mice overexpressing AR in brain (AR-Tg) to compare outcomes from MCAO in intact or castrated males and to evaluate the neuroprotective role of dihydrotestosterone (DHT) replacement in AR-Tg castrates. A further evaluation of AR overexpression in ischemic paradigms was performed using rat PC12 cells transfected with human AR and treated with oxidative and apoptotic stressors. We then studied the role of DHT in cultures overexpressing AR. Our results show (1) ischemia alters the expression of AR by decreasing AR mRNA levels, (2) AR overexpression is protective in vivo against MCAO in intact and castrated AR-Tg mice and in vitro against oxidative and apoptotic stressors in AR-PC12 cells, and (3) DHT does not enhance the protection triggered by AR overexpression in AR-Tg castrated mice nor in AR-PC12 cells.

References

  1. Endocrinology. 1999 Aug;140(8):3674-81 - PubMed
  2. J Neurosci. 1993 Sep;13(9):3669-80 - PubMed
  3. Exp Neurol. 1993 May;121(1):133-8 - PubMed
  4. FEBS Lett. 1996 Nov 11;397(1):50-4 - PubMed
  5. J Cereb Blood Flow Metab. 2009 Aug;29(8):1454-62 - PubMed
  6. J Cereb Blood Flow Metab. 2007 Sep;27(9):1553-62 - PubMed
  7. Proc Soc Exp Biol Med. 1999 Nov;222(2):145-9 - PubMed
  8. Steroids. 2010 Jun;75(6):404-10 - PubMed
  9. Cancer Res. 2001 May 1;61(9):3550-5 - PubMed
  10. Neuropathol Appl Neurobiol. 2009 Apr;35(2):156-64 - PubMed
  11. Annu Rev Biochem. 1994;63:451-86 - PubMed
  12. Stroke. 1998 Aug;29(8):1666-70 - PubMed
  13. J Neurobiol. 2005 Feb 15;62(3):341-51 - PubMed
  14. Cancer Res. 2004 Jan 15;64(2):765-71 - PubMed
  15. Genesis. 2004 Mar;38(3):139-44 - PubMed
  16. Proc Natl Acad Sci U S A. 1986 Feb;83(3):725-9 - PubMed
  17. J Cereb Blood Flow Metab. 2011 Jan;31(1):339-50 - PubMed
  18. Brain Res. 1998 Jun 15;796(1-2):296-8 - PubMed
  19. Exp Neurol. 1997 Jul;146(1):258-64 - PubMed
  20. J Neurosci Res. 1993 Jun 15;35(3):268-73 - PubMed
  21. Mol Cell Neurosci. 1994 Dec;5(6):587-96 - PubMed
  22. Endocrinology. 2004 Jul;145(7):3507-22 - PubMed
  23. Environ Health Perspect. 2008 Apr;116(4):474-80 - PubMed
  24. Brain Res. 2000 Jul 14;871(1):104-12 - PubMed
  25. J Neurosci. 2007 Apr 25;27(17):4642-9 - PubMed
  26. Cancer Cell. 2004 Nov;6(5):517-27 - PubMed
  27. J Neurobiol. 2003 Sep 5;56(3):293-302 - PubMed
  28. J Cereb Blood Flow Metab. 2004 Oct;24(10):1160-6 - PubMed
  29. J Appl Physiol (1985). 2002 Jan;92(1):195-201 - PubMed
  30. Int Rev Neurobiol. 2001;46:79-95 - PubMed
  31. Br J Cancer. 2003 Aug 4;89(3):552-6 - PubMed
  32. Neurochem Int. 2006 Jun;48(8):696-702 - PubMed
  33. Cancer Res. 1998 Oct 15;58(20):4640-5 - PubMed
  34. Proc Natl Acad Sci U S A. 1989 Jan;86(1):327-31 - PubMed
  35. Neuroscience. 2006;138(3):801-7 - PubMed
  36. J Pharmacol Exp Ther. 2004 Oct;311(1):237-45 - PubMed
  37. Arterioscler Thromb Vasc Biol. 1996 Jun;16(6):749-54 - PubMed
  38. APMIS. 2001 May;109(5):345-55 - PubMed
  39. J Cereb Blood Flow Metab. 2009 Mar;29(3):486-94 - PubMed
  40. Cancer Res. 1994 Oct 15;54(20):5474-8 - PubMed
  41. J Biol Chem. 2005 Mar 25;280(12):11583-9 - PubMed
  42. Neurosci Lett. 2009 Jan 30;450(2):196-200 - PubMed
  43. Steroids. 2010 Nov;75(11):754-9 - PubMed
  44. Horm Behav. 1994 Dec;28(4):492-502 - PubMed
  45. Methods. 2001 Dec;25(4):402-8 - PubMed
  46. Nat Med. 2004 Jan;10(1):26-7 - PubMed
  47. Proc Natl Acad Sci U S A. 1998 Feb 17;95(4):1852-7 - PubMed
  48. J Clin Endocrinol Metab. 2003 Sep;88(9):4043-54 - PubMed
  49. Nat Med. 1999 Mar;5(3):280-5 - PubMed
  50. Drug Discov Today. 2007 Mar;12(5-6):241-8 - PubMed
  51. Int J Dev Biol. 2004 Sep;48(7):645-53 - PubMed
  52. Endocrinology. 2006 Jun;147(6):3076-84 - PubMed
  53. Mol Cell Neurosci. 1991 Apr;2(2):117-22 - PubMed
  54. J Comp Neurol. 1990 Apr 1;294(1):76-95 - PubMed
  55. Endocrinology. 1999 Apr;140(4):1807-14 - PubMed

Publication Types